Patient Derived Xenograft Model Market Overview
The Patient Derived Xenograft Model Market is expanding as pharmaceutical and biotechnology companies increasingly use patient-derived models to evaluate cancer therapies and understand tumor biology. Growing emphasis on personalized medicine, rising cancer prevalence, and demand for predictive preclinical models are supporting market development.
According to the Market Research Future report updated September 15, 2026, the Patient Derived Xenograft Model Market was valued at USD 0.32 billion in 2024 and is projected to grow from USD 0.36 billion in 2025 to USD 1.25 billion by 2035, registering a CAGR of 13.3% during 2025–2035. Mice represent the largest model type, while Rats are the fastest-growing. Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, and other cancers constitute the major tumor categories, while Pharmaceutical and Biopharmaceutical Companies represent a major end-user group.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/reports/patient-derived-xenograft-model-market-12128
Key players driving innovation and competitiveness in the Patient Derived Xenograft Model Market include:
Charles River Laboratories
Crown Bioscience
Horizon Discovery
The Jackson Laboratory
OncoOne
Genentech
Eureka Therapeutics
MedImmune
Celerion
The market is being shaped by the growing use of patient-derived tumors in preclinical oncology research and the need for models that better reflect human tumor characteristics. Collaborations between pharmaceutical companies, biotechnology firms, and research institutions are strengthening model-development capabilities.
The Patient Derived Xenograft Model Market can be segmented by tumor type, model type, end user, and region. Tumor types include Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, and Other Cancer. Model types include Mice and Rats, while end users include Pharmaceutical and Biopharmaceutical Companies, Academic & Research Institutes, and CROs & CDMOs.
Opportunities are emerging through personalized oncology, genomic technologies, advanced model development, and outsourced preclinical research.
Recent Developments and Market Trends:
Personalized medicine is increasing demand for patient-derived models that can better represent individual tumor characteristics.
Genomic technologies are improving the characterization and selection of xenograft models.
Research collaborations are supporting the development of more sophisticated oncology models.
Growing cancer prevalence is increasing demand for preclinical drug-development platforms.
CROs and specialized research providers are expanding PDX-related services for pharmaceutical companies.
Reasons to Buy the Report:
Understand the market size and forecast through 2035.
Identify dominant and fastest-growing model types.
Analyze tumor-type and end-user opportunities.
Evaluate competitive developments among major providers.
Assess opportunities in personalized medicine and oncology research.
Future Outlook:
The Patient Derived Xenograft Model Market is expected to maintain strong growth as pharmaceutical R&D increasingly emphasizes predictive oncology models and personalized medicine. Mice are expected to remain the largest model type because of established protocols and extensive use in preclinical research, while Rats are positioned for faster growth as genetic-engineering capabilities advance. Pharmaceutical and Biopharmaceutical Companies will remain important end users, while CROs and CDMOs are expected to benefit from increasing outsourcing. North America is expected to remain an important market because of its established biotechnology ecosystem, while Asia-Pacific offers expanding opportunities through growing pharmaceutical research investment. Overall, the market is projected to reach USD 1.25 billion by 2035 at a CAGR of 13.3%.
➤➤Explore Our Latest Related Reports:
